본문 바로가기 주메뉴 바로가기

학술정보

Protocol

[eEnzyme] Getting ready for the 2024-2025 flu and Covid season

admin 2024-07-12 조회수 118

Enzyme LLC는 혁신적인 생명과학 기술을 통해 지속 가능한 솔루션을 제공하는 기업입니다.





Summer Newsletter

First, a bit of news on the recent influenza epidemic -- Earlier this year, there was an outbreak of HPAI H5N1 among U.S. dairy cattle, spreading across herds and causing fatal infections among some cats on affected farms, and spilling over into poultry. What was especially concerning was the four reported infections among dairy workers. A couple of days ago, NIH released a study on this H5N1 strain. Click here to read more.

Secondly, news on new COVID strains -- Currently, the KP.3, KP.2, and KP.1.1 strains are responsible for more than half the new cases, while the new highly transmissible LB.1 strain accounts for 1 in 10 cases. These variants are all descendants of the Omicron variant JN.1. Click here to read more.


2024-2025 Influenza Vaccine Composition

The World Health Organization (WHO) announced the recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. Click here for the webpage link.


According to the recommendation, the egg-based trivalent vaccine should contain


and the recombinant -based trivalent vaccine should contain


(Each is linked to the corresponding recombinant HA protein we've produced).

In addition, our pseudoviral particles for influenza strains will be available soon. Please stay tuned.

We have generated tools for studying SARS-CoV-2 and host interaction, and for validating or screening for the neutralizing antibodies. Check out the list of Cell Lines and Pseudoviral Particles we offer.


We also provide Pseudovirus Neutralization Assay ServicePlease contact us at info@eEnzyme.com.



eENZYME | 401 Professional Drive Suite 160 | Gaithersburg, MD 20879 US



eEnzyme - Official Distributor in South Korea "Morebio" 한국 공식 대리점 "모아바이오